Skip to main content
Premium Trial:

Request an Annual Quote

Fujeribio Buys IVD Controls Maker American Biological Technologies

NEW YORK (GenomeWeb News) – Cancer diagnostics and biomarker assays development company Fujeribio Diagnostics said today it has purchased American Biological Technologies, a maker of controls and calibrators for in vitro diagnostic assays, for an undisclosed sum.
 
The controls and calibrators ABT makes are used to confirm that diagnostic assay kits and the analyzers that they run on are operating within certain specifications, Malvern, Pa.-based Fujeribio said. Combining ABT’s control products and manufacturing capabilities with Fujirebio’s in vitro diagnostics, marketing resources, and customer partnerships will help the company realize the potential of ABT’s technology, Fujirebio VP of Marketing and Sales Monte Wiltse said in a statement.
 
“The acquisition is a natural next step on our path in entering diagnostic assay control and calibrator manufacturing, and mirrors Fujirebio Diagnostics’ strategy to provide its diagnostic industry customers with the tools and services that will revolutionize how disease is diagnosed and managed,” Fujirebio President and CEO Paul Touhey added.
 
Financial terms of the agreement were not released.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.